Compare Mesoblast Limited (MESO) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Quantum Computing Inc — how do they compare? Mesoblast Limited trades at $14.33 (market cap $1.75B), while Quantum Computing Inc trades at $7.4 (market cap $1.69B). The key difference: Mesoblast Limited and Quantum Computing Inc are close in size by market cap, and Mesoblast Limited is more actively traded (239,027 versus 7,991,522). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Quantum Computing Inc for 25 Days on average.
| MESO | QUBT | |
|---|---|---|
Market Cap | $1.75B | $1.69B |
Volume | 239,027 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $20.96 | $21.78 |
52-Week Low | $13.19 | $6.31 |
Typical Hold Time | 14 Days | 25 Days |
Enterprise Value | $1.83B | $753.24M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
QUBT trades at $7.39, down 3.02% today, amid a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 revenue of $5.6 million (Zacks Investment Research, 2026-09-08) but remains unprofitable with a net income margin of -152.45%. Recent news highlights the launch of Dirac-3S, scaling to 10,000 variables, with first shipments expected in Q4 2026 (PRNewsWire, 2026-10-01).
Analyst consensus is bullish with a $17.33 price target, but the stock faces significant risks from persistent losses, high cash burn, and competitive pressures. Investment appeal hinges on successful commercialization of quantum technology, though profitability remains distant. The company's $42.5 million backlog and liquidity provide some cushion against execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
